Trudy Oliver, Ph.D. | American Lung Association

This website uses cookies. By continuing you are agreeing to our privacy policy.

Trudy Oliver, Ph.D.

University of Utah
Funded by the American Lung Association of the Upper Midwest
Treating Genetic Differences in Small Cell Lung Cancer

Small cell lung cancer (SCLC) is the most aggressive subtype of lung cancer . Based on the long-standing belief that SCLC is a uniform disease, treatment is not currently influenced by genetic testing or patient stratification using molecular biomarkers. However, we recently discovered that SCLC is comprised of unique subsets driven by genes called MYC and MYCL, which have distinct features. Building on our discovery of a novel treatment for MYC-driven SCLC, we will use human cells and mouse models to identify therapies that will specifically target MYCL-driven SCLC. This work is expected to contribute to molecular testing of SCLC patients and to ultimately identify more effective treatment options for this deadly cancer.

Update: This year, we determined that these SCLC subtypes also harbor unique sensitivities to DNA damage and cell death, called apoptosis. Each SCLC subset has different expression levels of the anti-apoptotic protein BCL2, as well as different sensitivity to drugs that block BCL2. Our data suggest that BCL2 and other cell death proteins may represent novel drug targets for subtypes of SCLC.

Red button with telephone
Ask An Expert

Questions about your lung health? Need help finding healthcare? Call 1-800-LUNGUSA.

Get help
Red button of two hand prints
We need your generous support

Make a difference by delivering research, education and advocacy to those impacted by lung disease.

Button of turquoise LUNG FORCE swirl
What is LUNG FORCE?

LUNG FORCE unites women and their loved ones across the country to stand together in the fight against lung cancer.

Get involved
Join the fight for healthy lungs and healthy air.
Donate Now.